Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial

NCT05231629 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT05231629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05231629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 13, 2023
Completion date
December 31, 2029
Enrollment
300 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma